Table 1. β-catenin and E-cadherin mRNA expression in association with patients' clinicopathological features and E-cadherin protein immunohistochemical detection.
| (A) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
β-catenin mRNA |
E-cadherin mRNA |
E-cadherin IHC |
|||||||
| ND (n=7) | − (n=24) | + (n=6) | ND (n=6) | − (n=25) | + (n=6) | I (n=21) | II (n=10) | III (n=6) | |
| Gender | |||||||||
| Females | 2 | 11 | 2 | 3 | 12 | 2 | 6 | 4 | 3 |
| Males | 5 | 13 | 4 | 3 | 13 | 4 | 15 | 6 | 3 |
| Location | |||||||||
| Right | 2 | 8 | 2 | 2 | 8 | 3 | 8 | 6 | 2 |
| Left | 2 | 7 | 2 | 1 | 7 | 2 | 10 | 3 | 3 |
| Rectum | 3 | 9 | 2 | 3 | 10 | 1 | 3 | 1 | 1 |
| LN | |||||||||
| No | 5 | 4 | 3 | 3 | 3 | 5 | 1 | 4 | 2 |
| Yes | 2 | 20 | 3 | 3 | 22 | 1 | 20 | 6 | 3 |
| (P=0.018) | (P=0.001) | (P=0.012) | |||||||
| Grade | |||||||||
| Well/mod | 2 | 9 | 2 | 1 | 13 | 1 | 12 | 1 | 2 |
| Poor | 5 | 15 | 4 | 5 | 12 | 5 | 9 | 9 | 4 |
| Stage | |||||||||
| A | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 |
| B1-B2 | 2 | 8 | 2 | 1 | 6 | 4 | 4 | 4 | 2 |
| C1-C2 | 4 | 16 | 4 | 5 | 18 | 2 | 16 | 6 | 1 |
| Tumour Size | |||||||||
| 0–3 | 3 | 4 | 4 | 2 | 3 | 3 | 11 | 3 | 2 |
| 3.1–6 | 4 | 20 | 2 | 3 | 18 | 2 | 7 | 7 | 2 |
| 6.1–11 | 0 | 2 | 0 | 0 | 2 | 1 | 4 | 0 | 2 |
| (B) | |||||||||
|
β-catenin mRNA |
E-cadherin mRNA |
||||||||
| ND | − | + | ND | − | + | ||||
| E-cadherin IHC | |||||||||
| I | 3 | 17 | 4 | 2 | 23 | 0 | |||
| (P=0.003) | (P=0.001) | ||||||||
| II | 3 | 6 | 3 | 2 | 4 | 4 | |||
| III | 0 | 1 | 2 | 0 | 1 | 1 | |||
ND=no difference in mRNA expression between normal and tumour sample; LN=lymph node metastasis; mod=moderate; A-C2=Astler–Coller's classification.